Hyperion Therapeutics Announces Presentation of Long Term Data on Ammonia Control in Pediatric Patients Treated With RAVICTI® at the 12th International Congress of Inborn Errors of Metabolism and the Urea Cycle Disorder Satellite Symposium

Published: Sep 03, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced several data presentations at the 12th International Congress of Inborn Errors of Metabolism (ICIEM) and the satellite symposium on urea cycle disorders (UCDs) held in Barcelona, Spain. Among the presentations, the company highlighted long term data regarding ammonia control in pediatric patients with UCDs who were treated with RAVICTI® (glycerol phenylbutyrate) Oral Liquid. UCD patients lack enzymes or transporters necessary for the conversion of ammonia to urea and experience heightened levels of ammonia in the bloodstream. Left untreated, UCDs can result in neurological damage, coma, and/or death.

Help employers find you! Check out all the jobs and post your resume.

Back to news